Home » Stocks » CARA

Cara Therapeutics, Inc. (CARA)

Stock Price: $28.51 USD 0.20 (0.71%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
After-hours: $28.57 +0.06 (0.21%) Apr 16, 6:50 PM
Market Cap 1.42B
Revenue (ttm) 135.08M
Net Income (ttm) 8.41M
Shares Out 47.41M
EPS (ttm) 0.18
PE Ratio 161.07
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $28.51
Previous Close $28.31
Change ($) 0.20
Change (%) 0.71%
Day's Open 28.00
Day's Range 27.82 - 28.73
Day's Volume 632,804
52-Week Range 12.30 - 29.65

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

STAMFORD, Conn., April 07, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to allevi...

1 week ago - GlobeNewsWire

Cara (CARA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

1 week ago - Zacks Investment Research

Investors need to pay close attention to Cara Therapeutics (CARA) stock based on the movements in the options market lately.

1 week ago - Zacks Investment Research

The biotech stock is being added to an important small-cap index.

1 week ago - The Motley Fool

The shares of Cara Therapeutics Inc (NASDAQ:CARA) are up 13.1% to trade at $23.82  at last check -- their highest level in over a year -- on reports that the equity will be added to the S&P 600 SmallCap...

1 week ago - Schaeffers Research

Investors getting ready for another busy day of trading need to make sure they know the biggest pre-market stock movers before markets open. The post Today's Biggest Pre-Market Stock Movers: 10 Top Gain...

Other stocks mentioned: ACY, BTX, EEIQ, FHS, PSAC, VBLT, WEI ...
1 week ago - InvestorPlace

STAMFORD, Conn., March 31, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to allevi...

2 weeks ago - GlobeNewsWire

ST. GALLEN, Switzerland and STAMFORD, Conn., March 30, 2021 (GLOBE NEWSWIRE) -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the Eur...

2 weeks ago - GlobeNewsWire

The FDA accepts Cara Therapeutics (CARA) and Vifor Pharma's NDA for Korsuva injection under a priority review to treat moderate-to-severe pruritus in hemodialysis patients. Shares rise.

1 month ago - Zacks Investment Research

STAMFORD, Conn, and ST. GALLEN, Switzerland, March 08, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics (Nasdaq:CARA) and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has acce...

1 month ago - GlobeNewsWire

– U.S. FDA Accepts NDA Filing for KORSUVA™ Injection in CKD-aP –

1 month ago - GlobeNewsWire

On Thursday, February 25, Cara Therapeutics (NASDAQ:CARA) will release its latest earnings report. Decipher the announcement with Benzinga's help.

1 month ago - Benzinga

STAMFORD, Conn., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to allevia...

2 months ago - GlobeNewsWire

Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Investors need to pay close attention to Cara Therapeutics (CARA) stock based on the movements in the options market lately.

3 months ago - Zacks Investment Research

STAMFORD, Conn., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to allevia...

3 months ago - GlobeNewsWire

These 6 cannabis stocks show promise in the medical and recreational ends of the burgeoning marijuana sector, set to grow even more in 2021. The post 6 Cannabis Stocks to Buy as the U.S. Softens Its Sta...

Other stocks mentioned: CGC, GRWG, MRK, SNY, TRSSF
3 months ago - InvestorPlace

STAMFORD, Conn., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to allevia...

3 months ago - GlobeNewsWire

The opioid industry is an ~$50 billion annual business, but opioids are very harmful to the body and extremely addictive. CARA has a drug that is finishing its trials and expectation is that an NDA will...

4 months ago - Seeking Alpha

STAMFORD, Conn., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to allevia...

5 months ago - GlobeNewsWire

Cara Therapeutics, Inc. (CARA) CEO Derek Chalmers on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Cara (CARA) delivered earnings and revenue surprises of 48.53% and 86.25%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

– Conference call today at 4:30 p.m. ET –

5 months ago - GlobeNewsWire

STAMFORD, Conn., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to allevia...

5 months ago - GlobeNewsWire

Cara (CARA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

5 months ago - Zacks Investment Research

- Results from global KALM-2 p ivotal Phase 3 t rial of KORSUVA ™ Injection in h emodialysis p atients with p ruritus to be presented –

5 months ago - GlobeNewsWire

ST GALLEN, Switzerland & STAMFORD, Conn.--(BUSINESS WIRE)--Vifor Pharma and Cara Therapeutics sign US license agreement for i.v. Korsuva™* to treat dialysis patients with pruritus

5 months ago - Business Wire

- Cara to Host Conference Call Today at 8:30 am EDT -

5 months ago - GlobeNewsWire

STAMFORD, Conn., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to allevia...

6 months ago - GlobeNewsWire

Cara Therapeutics, Inc. (CARA) CEO Derek Chalmers on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Cara (CARA) delivered earnings and revenue surprises of 20.59% and 2.90%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

– Conference call today at 4:30 p.m. ET –

8 months ago - GlobeNewsWire

STAMFORD, Conn., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to allev...

8 months ago - GlobeNewsWire

STAMFORD, Conn., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to allevi...

8 months ago - GlobeNewsWire

Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

8 months ago - Zacks Investment Research

These marijuana stocks on the Nasdaq are top for value, growth, and performance for July 2020.

Other stocks mentioned: AMRS, CRON, GWPH, TLRY
9 months ago - Investopedia

STAMFORD, Conn., June 30, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to allev...

9 months ago - GlobeNewsWire

Both of these biotechs could have big catalysts on the way.

Other stocks mentioned: GWPH
9 months ago - The Motley Fool

These companies are all surprising a few doubters lately.

Other stocks mentioned: ARNA, FMS
9 months ago - The Motley Fool

Here are seven straightforward steps to help you invest in high-growth -- but high-risk -- marijuana stocks.

Other stocks mentioned: ACB, APHA, CGC, CRBP, CRON, GWPH, HEXO ...
10 months ago - The Motley Fool

- Patient enrollment increased approximately 28% to maintain > 80% statistical power for primary endpoint and key registration endpoint of  > 4-point improvement responder analysis -

10 months ago - GlobeNewsWire

These are the NASDAQ-listed marijuana stocks with the best value, fastest growth, and most momentum for June.

Other stocks mentioned: GWPH, VFF
10 months ago - Investopedia

Cara Therapeutics (CARA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

11 months ago - Zacks Investment Research

Cara Therapeutics, Inc. (CARA) CEO Derek Chalmers on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Cara (CARA) delivered earnings and revenue surprises of 1.59% and 67.56%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

Which stock wins in a battle between these two clinical-stage biotechs?

Other stocks mentioned: SGMO
11 months ago - The Motley Fool

Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

11 months ago - Zacks Investment Research

The company plans to submit its pruritis drug for FDA and EMA approval later this year.

11 months ago - The Motley Fool

As of late, it has definitely been a great time to be an investor in Cara Therapeutics.

11 months ago - Zacks Investment Research

About CARA

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe chronic kidney disease-assoc... [Read more...]

Industry
Biotechnology
IPO Date
Jan 31, 2014
CEO
Derek Chalmers
Employees
80
Stock Exchange
NASDAQ
Ticker Symbol
CARA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for CARA stock is "Buy." The 12-month stock price forecast is 35.13, which is an increase of 23.22% from the latest price.

Price Target
$35.13
(23.22% upside)
Analyst Consensus: Buy